SCHEMBL7560269

SCHEMBL7560269

O=C(NN=Cc1ccc(-c2ccc([N+](=O)[O-])cc2)o1)c1[nH]c2ccccc2c1-c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.58
KMT2A Q03164 14/20 0.58
MEN1 O00255 13/20 0.58
HTT P42858 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 3/20 0.56
KDM4E B2RXH2 2/20 0.56
TDP1 Q9NUW8 1/20 0.56
POLB P06746 3/20 0.56
PSMD14 O00487 2/20 0.56
HTR1E P28566 1/20 0.54
S1PR3 Q99500 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.52
RAB9A P51151 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
PKM P14618 2/20 0.51
GAA P10253 1/20 0.51
RECQL P46063 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7560264 1.00 MAPT (0.58) MAPTKMT2AMEN1HTTALDH1A1
SCHEMBL7561691 0.87 MAPT (0.58) MAPTKMT2AMEN1HTTALDH1A1
SCHEMBL7529241 0.87 TUBB4A (0.54) MAPTKMT2AMEN1ALDH1A1MAPK1
SCHEMBL7561687 0.87 MAPT (0.58) MAPTKMT2AMEN1HTTALDH1A1
SCHEMBL7673563 0.87 TUBB4A (0.54) MAPTKMT2AMEN1ALDH1A1MAPK1
SCHEMBL7563854 0.86 MEN1 (0.57) MAPTKMT2AMEN1HTTALDH1A1
SCHEMBL7563859 0.86 MEN1 (0.57) MAPTKMT2AMEN1HTTALDH1A1
SCHEMBL7678017 0.81 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1MAPK1
SCHEMBL7678021 0.81 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1MAPK1
SCHEMBL7679897 0.81 MAPT (0.57) MAPTKMT2AMEN1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MAPT 4828/4885KMT2A 2765/4885MEN1 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.